Regular International Journal of Integrative Biology A journal for biology beyond borders



Molecular characterization and expression of human Rotavirus recombinant protein VP2, VP6, and VP7 transfected in Vero cell

Latri Rahmah^{1,2,*}, Ernawati G Rachman², Debbie S Retroningrum², Marselina I Tan²

¹ Rotavirus Vaccine Production PT Biofarma, Bandung, Indonesia ² Institut Teknologi Bandung, Bandung, Indonesia

Submitted: 21 Nov. 2016; Revised: 9 Feb. 2017; Accepted: 15 Feb. 2017

Abstract

Rotavirus is a non-enveloped viruses containing double-stranded RNA genetic material. The 11 ds-RNA encodes 6 structural and 6 nonstructural proteins. Three major structural capsid proteins of human rotavirus RV4 (VP2, VP6, and VP7) had been isolated, cloned and transfected into Vero cell. VP2 (VP2LRV4), VP6 (VP6LRV4), and VP7 (VP7LRV4) was isolated with the size of coding sequence (CDS) 2673 bp, 1194 bp, and 981 bp, respectively. In silico analysis showed that VP2LRV4, VP6LRV4, and VP7LRV4 protein sequences (prediction) comprised essential subdomain and residues to construct triple layer structural capsid protein. Gene transcription and protein expression of VP2LRV4, VP6LRV4 and VP7LRV4 in Vero cell were examined by RT-PCR and immunofluorescence assay (IF). Transcriptional analysis led to the detection of VP6 and VP7 cDNA on day 1 post transfection while VP2 cDNA was expressed on day 3 post transfection.

Keywords: Rotavirus; Vero Cell; VP2; VP6; VP7.

INTRODUCTION

Rotavirus has been recognized as a major cause of infantile diarrhea in young children. Classify as nonenveloped virus, the genomes of Rotavirus are 11 ds-RNA which encoding 6 structural proteins (VP1-VP4, VP6, and VP7) and 6 nonstructural protein (NSP1-NSP6) (Desselberger, 2014). Rotavirus is composed by three layers (outer, inner and core) capsid protein. In the core site, VP2 is a major protein with VP1 and VP3 as the minor protein. The major capsid protein VP6, which comprises >80% of the protein mass of the particle, is located on the inner capsid and contains the subgroup antigen. The rotavirus outer layer is composed of the glycoprotein VP7 and VP4 (Ruiz *et al.*, 2009).

A number of research reported that the recombinant structural protein of Rotavirus had been expressed in prokaryotic host cell, such as *Escherichia Coli*, and

*Corresponding author: Latri Rahmah, Ph.D. Rotavirus Vaccine Production PT Biofarma, Bandung, Indonesia Email: rahmah_latri@yahoo.com; latri.rahmah@biofarma.co.id eukaryotic host cell such as yeast, insect cell, and mammalian cell system. However the expression of recombinant structural protein found several limitations. Rotavirus recombinant protein produce in Escherichia coli failed to express and folded properly (Kato *et al.*, 2012). In yeast, it is produced in a lower quantity or inadequate aggregation condition related to glycosylation patterns (Rodriguez-Limas *et al.*, 2011). In Baculovirus system, recombinant Rotavirus protein is degraded and partial loss of ability to form trimmers (Da silva *et al.*, 2012).

Mammalian cells have been chosen as a system for the production of recombinant proteins for its excess on proper protein folding, assembly, and post-translational modification. Vero cells is a mammalian cells that has been widely used for expression recombinant virus protein, such as JEV, PPRV, SV40, rabies, Coronavirus (SARS), Ebola, and Influenza (Hua *et al.*, 2014; Mulherkar *et al.*, 2011; Chen *et al.*, 2011; Siu *et al.*, 2008; Balamurugan *et al.*, 2006; Hsieh *et al.*, 2005; Konishi *et al.*, 2001; Wagner *et al.*, 2000). In the current study, we used Vero cell as mammalian expression system to generate the three major structural recombinant Human Rotavirus RV4 capsid proteins.

MATERIALS AND METHODS

Amplification and cloning of VP2, VP6, and VP7 rotavirus gene

Amplification of the complete open reading frame (ORF) of VP2, VP6, and VP7 gene of rotavirus RV4 strain was preformed using RT-PCR. Amplification of VP2, VP6, and VP7 were using primer's pair VP2, VP6 and VP7. RT-PCR was performed with an aliquot of dsRNA (100 ng), 4µM each of specific primer, 2x Reaction Mix (a buffer containing 0,4mM of each dNTP, 2.4 mM MgSO₄) (Invitrogen) and 1U Super ScriptTM III RT/Platinum Taq High Fidelity Enzyme Mix (Invitrogen) in a final volume 50 µL. The full-Length VP2 (2.6 kb) cDNA synthesis was obtained by one cycle at 45 °C for 45 min, followed by PCR amplification with 35 cycles at 94 °C for 1 min, 62 °C for 2 min, 72 °C for 2 min and 1 cycle at 72 °C for 7 min. The full-Length VP6 (1.3 kb) cDNA synthesis was obtained by one cycle at 45 °C for 45 min, followed by PCR amplification with 35 cycles at 94 °C for 1 min, 47 °C for 2min, 72 °C for 2 min and 1 cycle at 72 °C for 7min. The full-Length VP7 (1 kb) cDNA synthesis was obtained by one cycle at 45 °C for 45 min, followed by PCR amplification with 35 cycles at 94 °C for 1 min, 42 °C for 2min, 72 °C for 2 min and 1 cycle at 72 °C for 7min. The amplified cDNA of VP2 gene was cloned into pCDNA 3.1/TOPO while VP6 and VP7 gene was cloned into pEF6/V5-His-TOPO. Both vectors are dualhost vectors (Invitrogen) for both bacteria and mammalian cells and protein expression in mammalian cells. The recombinant VP2-pCDNA, VP6-pEF, and VP7-pEF was transformed into competent E.Coli Top 10 and ampicillin-resistant colonies were screened by ampicillin medium selection. In addition the expected inserts were verified by colony PCR. Colonies PCR were performed using primer's pairs VP2, VP6, and VP7 as described above. Finally, nucleotide sequences analyses were carried out to obtain the full sequences of genes and to confirm the exact in-frame position and correct orientation for subsequent expression.

Protein sequence and structure analysis

Protein sequences (prediction) of VP2, VP6, and VP7 were performed using Bioinformatics tools Expasy. Three dimensional structures of VP2, VP6, and VP7 were implemented via Phyre2 and Pymol Molecular Graphic System.

Transfection

Vero Cell were seeded at a concentration 1.5×10^4 cells per well in 96–well plates and grown in Opti-MEM for 1 d prior to transfection. To achieve transfection, according to the manufacturer's instruction, 0,2 µg of Recombinant Vector (pCDNA/VP2, pEF/VP6, pEF/VP7) were mixed with 0.5 µL lipofectamine 3000^{TM} , 0.4 µL P3000 reagent, and 10 µL Opti-MEM (Invitrogen) according to the instruction supplied by the company. Transfection mixture was then added to the seeded cells and incubated at 37 °C from day 1 to 5 for transfection.

RT-PCR analysis

Vero cells transfected with Recombinant Vector (pCDNA/VP2, pEF/VP6, or pEF/VP7) washed two times with PBS and RNA total was extracted by SV Total RNA isolation System (Promega) according to the manufacturer's instruction. The expected fragment of VP2, VP6, and VP7 was amplified by RT-PCR using the primer's pair described above.

Immunofluorescence Assay

Vero cells transfected with Recombinant Vector (pCDNA/VP2, pEF/VP6, or pEF/VP7) fixed in methanol-acetone (1:1) and incubated for 10 m. After fixation, the cells were added by blocking solution (BSA 1%, in PBS-Tween 0.05%) followed with rabbit anti-RV polyclonal antibody (1:800 in PBS). Second-stage antibody was Alexa-488-conjugated secondary antibody diluted at 1:500 in PBS. Cells were examined with a Fluorescence Microscope.

RESULTS AND DISCUSSION

The complete VP2 cDNA sequences (VP2LRV4) with 2679 nucleotides in length contained a 2673 bp CDS that encoded 889 amino acids (Fig. 1A). The complete cDNA sequences (1356 bp) of VP6 (VP6LRV4) comprised an 1194 bp encoding a peptide of 397 amino acids (Fig. 1B). The VP7 sequence (VP7LRV4) was 1062 consecutive bases and contained CDS with 981 bp that encoded 326 amino acids (Fig. 1C). In silico study showed that protein structure (prediction) of VP2LRV4, VP6LRV4, and VP7LRV4 comprised essential subdomain and residues to construct the structural capsid protein (Fig. 2).

The three dimensional structure (prediction) at Figure 2.A showed the dimer domain of VP2LRV4. The dimer subdomain of VP2LRV4 was predicted located in residues 711 to 836 (Fig. 1A). The dimerization of VP2 performed on its dimer domain at residues ~700-826 (Boudreaux *et al*, 2013; McClain *et al*, 2010). Protein structure (prediction) of VP6LRV4 in Fig. 2B showed the domains and residue that was predicted essential to perform trimerization. The essential domain of VP6LRV6 to performed trimerization was predicted located in residues 1 to 150 and residues 151 to 331 (Fig. 1B). Mathieu, *et al* (2001) reported that the VP6 subunit performed trimerization at the domain B (residues 1-150) and domain H (residues 151-331) to construct inner layer Rotavirus capsid protein.

A. VP2LRV4

1 A:	G GC	G TAC	AGG	AAG	CGC	GGA	GCT	AAA	CGI	GAA	A AA	C TT	A CO	A C	AA (CAA	AAT	GAA	CGT	CTO	G CA	A GA	A A	A GA	A A	TT G	AA A	AAA	GAT	GTG	GAT	GTA	ACT	ATG	GAA	AAT	AAA	AAT	AAC	AA'	T AG	A AA	G CA	G CAA	A TTA	TCT	135
136 G	T AF	A GTA	CTA	TCA	CAA	AAA	GAG	GAA	ATA	ATA	A AC	T GA	T GO	TA C	AA (SλT	GAT	ATT	AAA	ATA	A GC	T GG	T GA	G AT	TT A	AA A	AA 1	TCA	TCA	AAA	GAA	GAG	TCA	AAA	CAG	TTG	CTC	GAA	ATA	A TT	A AA	A AC	A AA	A GAZ	A GAC	CAT	270
271 C	G AZ	A GAA	ATA	CAG	TAT	GAA	ATT	CTA	CAR	AAA	A ACI	G AT	A CO	GA	CT :	TTT	GAA	TCC	AAA	GAJ	A TC	A AT	T TT	G AJ	A A	AA T	TA C	GAA	GAT	ATA	AGA	CCG	GAG	CAA	GCT	AAG	AAG	CAA	ATG	AA	A TTO	G TT	T AG	A ATA	A TTT	GAA	405
406 C	A AA	A CAA	TTA	CCA	ATC	TAT	CGA	GCA	AAT	GGT	C GA	G AA	A GA	A T	TG Z	AGA	AAC	AGA	TGG	TAT	T TG	G AA	A TI	G AF	A A	AG G	AT 7	ACG	CIG	CCA	GAC	GGA	GAT	TAT	GAT	GTA	CGA	GAA	TAT	TTT 1	T TTZ	A AA	T TT	A TAT	GAT	CAG	540
541 A:	C CI	G ATA	GAA	ATG	CCA	GAT	TAT	TTG	CTP	CTG	AA	A GA	T AT	GG	CT (STA	GAA	AAT	AAA	AA	T TC	T AG	A GA	T GO	CT G	GT A	AA G	GTT	GTA	GAT	TCT	GAA	ACA	GCA	AAT	ATT	TGT	GAT	GCI	I AT	A TT	T CA	A GA	I GAR	A GAG	ACG	585
676 GI	G GG	A GTT	GTC	AGA	AGA	TTC	ATT	GCA	GAT	ATG	G AG	A CA	A CA	G G	TT (CAG	GCT	GAT	AGA	AA	T AT	T GI	C AL	C TI	AT C	CA 1	ICA I	ATT	TTA	CAT	CCG	ATT	GAT	CAT	GCA	TTT	AAT	GAA	TAT	TTT 1	T CT	A AA	T CA	T CAR	A TTA	GTC	720
811 GJ	LA CO	A CTA	AAT	AAT	GAA	ATC	ATT	TTT	AAT	TAT	TAT	A CC	A GA	LA A	GA I	ATA	AGG	AAT	GAT	GT	T AA	CIA	T AT	T TT	IG A	AT A	TG C	GAT .	ATG	AAT	TTG	CCA	TCA	ACA	GCA	AGA	TAT	ATT	AGA	L CC	A AA	T TT	A TT	G CAJ	A GAT	AGA	945
946 C.	A AA	T TTA	CAT	GAT	AAT	TTT	GAA	TCA	TTZ	TGO	GA	C AC	A A	AA	CT I	ACA	TCA	AAT	TAT	ATA	A CT	A GC	C AC	A TO	CA G	TT G	TG C	CCT	GAT	TTG	AAG	GAA	AAA	GAA	TTA	GTT	TCA	ACT	GAA	GC"	T CA	G AT	A CA	G AAA	A ATG	TCT	1080
1081 CA	A GA	T TTG	CAA	CTT	GAA	GCC	TTA	ACG	ATA	CAP	A TC	T GA	A AC	GC	AG 1	TTT	CTT	GCT	GGC	ATA	A AA	T TC	CA CA	A GO	CA G	CA A	AT 0	GAT '	CGT	TTT	AAA	ACA	TTG	ATA	GCA	GCT	CTG	TTA	AGO	CAC	G CG	T AC	A AT	G TCA	A TTA	GAT	1215
1216 T	T GI	A ACC	ACG	AAT	TAT	ATG	TCA	CTT	ATA	TCT	C GG	T AT	G TG	G C	TA :	TTG	ACC	GIT	ATA	CC2	A AA	T GA	C AT	G TT	TT C	TT C	GT G	GAA	TCA	TTA	GTC	GCA	TGC	GAA	TTG	GCC	ATA	ATA	AAT	AC:	T AT	A GT	T TA	T CCF	A GCA	TTT	1350
1351 G0	A AT	S CAA	AgA	ATG	CAT	TAT	AGA	AAT	GGT	GAT	CCC	C CA	G AC	TC	CG :	TTT	CAA	ATA	GCA	GAJ	A CA	G CA	A A	A CI	A A	AT T	TTT C	CAA	GTA	GCT	AAT	TGG	TTA	CAT	TTT	ATT	AAT	AAT	AAT	AG	A TT	T AG	G CA	A GTT	GTT GTT	ATT	1485
1486 G	T GO	A GTG	TTA	AAT	CAA	ACA	CIT	AAC	GAT	AAT	TA 1	T AG	G AA	T G	GA (CAA	GTT	ATT	AAT	CAC	G TT	A AT	G GZ	A GO	CA T	TA A	TG C	CAG	CTA	TCT	AGA	CAA	CAA	TTT	CCG	ACT	ATG	CCA	GTT	GA'	T TAT	T AA	A AG	A TCZ	A ATC	CAA	1620
1665 T	A AC	A AGA	TTA	GTA	TCA	TAT	AAT	TAT	GAR	ACT	CTI	A AT	G GC	TT	GT (STA	ACT	ATG	AAT	ATO	G CA	A CA	T GI	T CZ	A A	CT C	TC A	ACT .	ACC	GAA	AAA	TTA	CAA	TTA	ACT	TCT	GTC	ACA	TCT	I TT	A TG	T AT	G TT	A ATT	GGA	AAT	1800
1801 A	T AC	A GTA	ATT	CCA	AGT	CCA	CAA	ACA	TTa	TTT	CA	C TA	T TA	T A	AC (STA	AAT	GTA	AAT	TTT	T CA	T TC	A A	T TP	AT A	AC G	AA C	CGA .	ATT	AAC	GAC	GCA	GTG	GCT	ATC	ATT	ACG	GCT	GCI	AA:	T AG	A CT	A AA	C TTF	TAT A	CAG	1935
1935 A	LA AZ	A ATG	AAA	TCA	ATA	GTT	GRG	GAT	TTT	TTO	AN	A AG	A TT	GC	AA I	ATT	TTT	GAT	GTA	CCZ	A CG	A GI	TA CO	A GI	AT G	AC C	AA I	ATG	CAC	AGG	TTG	AGA	GAT	AGA	CIT	AGA	TTA	TTA	CCA	GT:	T GAL	A AG	A CG	A AGO	CTT	GAT	2070
2071 A	TA TT	T AAT	TTA	ATA	TTA	ATG	AAT	ATG	GAG	CAG	ATI	C GA	A CO	A G	CT :	TCA	GAT	AAA	ATT	GCT	T CA	A GG	A GI	A AT	TA A	TT G	CT 1	TAT .	λGA	GAT	ATG	CAA	CTA	GAA	AGA	GAT	GAG	ATG	TAT	GG	A TA	T GT	C AA	C ATT	GCT GCT	AGa	2205
																					Gl	n Gl	v Va	1 II	Le I	le A	la 1	Tyr .	Arg	Asp	Met	Gln	Leu	Glu	Arg	Asp	Glu	Met	Tyr	G1	y Typ	r Va	1 As	n Ile	Ala	Arg	
																					Di	mer	formi	ng su	bdon	nain																					
2205 A	T CI	C GAT	GGA	TAT	CAA	CaA	AtT	AAc	CTa	gad	GA	G TT	G AT	GA	GA I	ACT	GGA	GAC	TAT	GGG	G CA	A AT	T AC	TA	AT A	TG 1	TA I	TTA .	AAC	AAT	CAG	CCT	GTA	GCT	TTA	GTA	GGG	GCA	TTA	L CC	A TT	T GT	G AC	G GAT	TOT 1	TCA	2340
A	in Le	a Asp	Gly	Tyr	Gln	Gln	Ile	Asn	Leu	Glu	ı Glı	u Le	u Me	t A	rg :	Thr	Gly	Asp	Tyr	Gl	y Gl	n Il	e Th	nr As	an M	let I	eu I	Leu .	lsn	Asn	Gln	Pro	Val	Ala	Leu	Val	Gly	Ala	Leu	ı Pre	o Phe	e Va	1 Th	r Asp	Ser	Ser	
2341 G	T AT	A TCA	CTC	ATT	GCA	AAA	TTA	GAT	GCI	ACF	A GT	т тт	T GO	T C	AA J	ATA	GTT	AAA	CTT	AG	A AA	A GI	G GI	C AC	ст с	TA A	AA O	CCA .	ATA	TTG	TAT	AAG	ATA	AAT	TCT	GAT	TCT	AAT	GAT	. TT	C TA	с тт	A GT	T GCZ	A AAT	TAT	2385
V	1 11	e Ser	Leu	Ile	Ala	Lys	Leu	Asp	Ala	The	va:	l Ph	e Al	a G	ln :	Ile	Val	Lys	Leu	Arg	g Ly	s Va	al As	p Th	nr L	eu I	ys I	Pro	lle	Leu	Tyr	Lys	Ile	Asn	Ser	Asp	Ser	Asn	Asp	> Phe	e Ty:	r Le	u Va	l Ala	Asn	Tyr	

2475 GAT TON AND ACC ACA ACT TOA ACC ACA ABA GTC TAT ABA CAB GTC ACA CCA CCT THT GAT TIC AGA GTG TCA ANG CAT ANG THA ACG TOT ABI THG ACT THT ACA GTT TAT TOT GAT THA TOT THC GTT TOT GCA 2610 Asp Trp Ile Pro Thr Ser Thr Thr Lys Val Tyr Lys Gin

2611 GAC ACE GIT GAA CCC ATT AAC GCA GIT GCT TIT GAC AAT AIG CGC ATT ATG AAC GAA CTG TAA 2673

B. VP6LRV4

1	ATG	GAG	GTT	CIG	TAT	TCA	TTG	TCA	AAA	ACT	CTT	AAA	GAT	GCT	AGG	GAT	AAA	ATT	GTT	GAA	GGT	ACA	CTA	TAC	TCC	AAT	GTT	AGC	GAT	CIC	ATT	CAA	CAA	TTT	AAT	CAA	ATG	ATA	GTG	ACT	ATG	AAT	GGA	AAT	GAC	135
1	Do	mai	B	- T	I	2	T.	2	ĸ	1	T.	ĸ		A	R	U	ĸ	+	v	-	G	1	т	I	2	IN .	v	2	U.	+	x	×	1	14	x	M	1	v	1	M	N	G	IN	5	7	45
136	TTT	CAA	ACT	GGA	GGA	ATT	GGT	AAT	TTA	CCT	GTT	AGA	AAT	TGG	ACT	TTT	GAT	TTT	GGT	CTA	TTA	GGT	ACA	ACA	CTT	ATT	AAT	TTG	GAT	GCT	AAT	TAT	GTT	GAA	AGT	GCA	AGA	ACT	ACG	ATT	GAA	TAT	TTC	ATT	GAT	270
46	F	Q	Т	G	G	I	G	N	L	P	V	R	N	W	Т	F	D	F	G	L	L.	fe	T	TT	L	L	N	L	D	A	N	Y	V	Е	S	A	R	Т	Т	I	E	Y	F	I	D	90
271	TTT	ATC	GAT	DAC	GTA	TGT	ATG	GAT	GDD	ATG	GCA	AGA	GAG	TCT	CDD	AGA	AAT	GGL	GTA	GCT	CCA	CAA	TCT	GAD	GCG	TTG	AGG	ANG	TTA	TCA	GGC	ATT	555	TTT	ANG	AGA	ата	DAT	TTT	GAT	DAT	TCA	TCA	GAD	TAT	405
91	F	I	D	N	V	C	M	D	E	M	A	R	E	S	Q	R	N	. G_	V	A	P	Q	S	E	A	L	R	K	L	S	G	I	K	F	K	R	I	N	F	D	N	S	S	E	Y	135
																		10-1	1							possore)		10000000																		-
406	ATA	GAA	AAT	TGG	AAT	CTA	CAA	AAT	AGA	AGA	CAG	CGT	ACT	GGA	TTT	GIC	TTT	CAT	AAA	CCT	AAT	ATA	TTT	CCA	TAC	TCA	GCT	TCG	TIC	ACT	TTA	TAA	AGA	TCT	CAA	CCA	ATG	CAT	GAT	TAA	TTA	ATG	GGA	ACT	ATG	540
100		2	IN	п	IN	P.	×	24	R	R	¥	R	1	G	1	Do	main	H	- n	P	IN I	1	1	P	I	2	A	2	1	ъ	IN	R	2	×	P	m	п	D	IN	Ъ	M	G	1	m	1	160
541	TGG	CIT	AAT	GCT	GGA	TCA	GAG	ATA	CAA	GTA	GCT	GGT	TTT	GAT	TAT	TCA	TGT	GCT	ATA	AAC	GCA	CCA	GCA	AAT	ATA	CAG	CAG	TTC	GAA	CAT	ATT	GTG	CAG	CTT	AGA	CGT	GCA	CTA	ACT	ACA	GCT	ACT	ATA	ACT	TTG	585
181	W	L	N	A	G	S	Е	I	Q	V	A	G	F	D	Y	S	С	A	I	N	A	P	A	N	I	Q	Q	F	Е	Η	I	V	8	L	R	R	A	L	Т	Т	A	Т	I	Т	L	225
676	TTA	CCT	GAT	GCG	GAA	AGA	TTC	AGT	TTT	CCA	AGA	GTT	ATC	AAT	TCG	GCT	GAC	GGC	GCA	ACT	ACA	TGG	TTC	TTT	TAA	CCA	GTT	ATT	CTA	AGA	CCA	TAA	TAA	GTA	GAA	GTA	GAG	TTT	TTA	TTG	TAA	GGA	CAA	ATT	ATT	810
226	L	P	D	A	E	R	F	S	F	P	R	V	I	N	S	A	D	G	A	Т	Т	W	F	F	N	P	V	I	L	R	P	N	N	V	E	V	E	F	L	L	N	G	Q	I	I	270
																																						-		_		P	ro-3	13		1
811	AAC	ACA	TAT	CAG	GCT	AGA	TTT	GGT	ACT	ATT	ATC	GCA	AGA	AAT	TTT	GAT	ACA	ATT	CGG	TIG	TCA	TTT	CAG	TTA	ATG	CGT	CCA	CCA	AAT	ATG	ACA	CCA	GCT	GIT	AAC	GCA	TTA	TTT	CCG	CAA	GCG	CAA	CCT	TTT	CAA	945
271	N	Т	Y	Q	A	R	F	G	Т	I	I	A :	A	R	F	D	Т	I	R	L	S	F	Q	L	M	R	P	P	N	М	Τ	P	A	V	N	A	L	F	P	Q	A	Q	Ρ	F	Q	315
946	TAC	CAT	GCA	202	GTT	GGN	CTC	202	TTA	CGT	ATT	GNA	TCT	CCT	GTC	TCC	GNA	TCA	GTG	CTT	ece.	GAC	606	AAT	GNA	ACT	CTG	TTA	ece.	ллт	GTG	ACT	606	GTA	CGT	C33	GNG	тат	CCT	ATA	CCA	GTT	GGA	TCA	GTA	000
316	Y	H	A	T	V	G	L	T	L	R	I	E	S	A	V	C	E	S	V	L	A	D	A	N	E	T	L	L	A	N	V	T	A	V	R	O	E	Y	A	I	P	V	G	S	V	330
																																														-
991	TGC	GAA	TCA	GIG	CTT	GCG	GAC	GCG	AAT	GAA	ACT	CIG	TTA	GCG	AAT	GIG	ACT	GCG	GTA	CGT	CAA	GAG	TAT	GCT	ATA	CCA	GTT	GGA	TCA	GTA	TTT	CCA	CCA	GGC .	ATG	AAT	TGG	ACT	GAG	CTA	ATT	ACT	AAC	TAT	ICA	1125

1126 CCA TCT AGA GAA GAT AAC CTG CAA CGC GTC TTT ACA GTA GCT TCC ATT AGA AGC ATA TTG ATT AAG TGA 1194

C. VP7LRV4

ATG GAT GGT ATT GAA TAT ACC ACA ATT CTA ATC TIT CTG ATA TCA ATT GTA CTC AAC TAT ATA GTG ACT CGA ATA ATG GAC TAC ATT ATA AGA TIT TTG TTG ATT ACT GTA GCA TTA TT 135 M Y G I E Y T T I L I F L I S I I L L N Y I L_{AST-69}^{AST-69} S V T R I M D Y I I Y R F L L I S V A L F 45 1 GCA TAC GCT AAC T A Y A N CT ACT CAA GRA GGA ATA ITI CTA ACA ICI ACA ITA IGI TIG IAI TAI CCA ACI GAA GCA AGI 270 S T Q E G F L T S T L C L Y Y P T E A S I 90 271 91 ACT CAA ATC AAT GAT GGT GAA IGG AAA GGC TCA TIG ICA CAA ATG TIT CTC ACA AAA GGT IGG CCA ACA GGA ICA GTC IAI TIT IAA GAG IAI ICA AGT AIT GIT GAT ITI TCT GTI GAC CCA CAA ITA TAT IGT 405 T Q I N D G E N K D S L S Q M F L T K G N P T G S V Y F K E Y S S I V D F S V D P Q L Y C 135 GAT CAA AAI CTI GAA TIA GAT AIG TCA GAG TIA GCI GAI TIA ATA TIG AAI GAA TGG TIA IGT AAI CCA AIG GAT AIA ACA TIA TAI TAI CAA CAA TGG GGA GAA 450 D Q N L E L D M S E L A D L I L N E W L C N P M D I T L Y Y Y O O S G E 150 406 GAT TAT AAC TIA GTA CTA ATG AAA TAT TGG ATA TCA ATG GGA ICA TGT ACT GTG AAA GTG TGT CCA CTG AAT ACG CAA ACG TTA GGA ATA GGT IGT CAA ACA ACA AAT GTA GAC TCG TTT GAA ATG GTC GCT GAG AAT GAA GAA TTA GCT 585 W I S M G S S C T V K V C P L N T Q T L G I G C Q T T N V D S F E M V A E N E K L A 195 541 181 a se GGG ATA AAT CAT AAA ATA AAT TIG ACA G I N H K I N L T 676 226 ACT ATT CGA AAT T I R N ang ang ita ggi cca aga gag ani gia gci gta aia caa gii ggi ggc ici ani gta iia gac 720 K K L G P R E N V A V I Q V G G S N V L D 240 811 ACT AAT CCA N P AGA ATG ATG AGA R M M R AAA TGG tgg caa gta tit tat act ata gta gat tat att aac cag atc gta cag gta atg tcc aaa aga tca aga 855 w Q v f y t i v d y i n Q i v Q v m s k r s r 285 $^{\circ}$ ACT T 0 F ICA TTA AAT ICI GCA GCI ITI TAT TAT AGA GTA TAG S L N S A A F Y Y R V STOP 981

Fig 1: Full nucleotide sequences of VP2LRV4 (A), VP6LRV4 (B), and VP7LRV4 (C).

VP6LRV4 also comprised essential residues 65-LLGTTLL-71, His-153, and Pro-313 (Fig. 1B). Mathieu, *et al* (2001) reported that the VP6 trimmer contained a metal ion that located at the center of the molecule, on the 3-fold molecular axis, coordinated to residue His-153. Previous study had reported the particular segment 65-LLGTTLL-71 of VP6 that facilitated the interaction with VP2 and residue Pro-331 that contacted with residues Pro-279 and Thr-281 of VP7 (Chen *et al*, 2009; Mathieu *et al*, 2001). Fig. 1C showed residues Pro-279, Thr-281, Asn-69 and Asn-238 that were predicted essential in VP7. Chen *et al*, (2009) reported that residues Pro-279 and Thr-281 of VP7 interact with VP6 protein. The VP7LRV4 also comprised residues Asn-69 and 238 (Fig. 2). Previous study reported that residues Asn-69 and 238 of RV4 were conserved as N-Glycosylated residue (Coulsoun and Kirkwood, 1991).

The three genes of Rotavirus major structural protein, VP2, VP6, and VP7, have been introduced into Vero Cell using transient transfection. The transient gene expression (TGE) in mammalian cells is configured as an alternative methodology for the rapid production of

recombinant proteins (Jager *et al.* 2007). In this paper, the transient expression of recombinant VP2, VP6 and VP7 of RV4 was described for the first time in Vero cells.

The transcription of VP2, VP6, and VP7 gene in transfectant Vero cells was verified by the RT-PCR analysis. Agarose gel electrophoresis of the RT-PCR products obtained from total RNA extracted from Vero cells that was with transfected the pCMV/VP2, showed expected fragment of 2.6 kb at day 3 post transfection (pt) to day 5 pt (Figure 3). The RT-PCR confirmed that VP2 mRNA was expressed in transfectant Vero cells at day 3 and acquired the highest expression at day 5. These data may indicate that the production of rVP2 protein in Vero cell optimize at day 3 to 5. Several researches also suggest that rVP2 in transfected cells expressed on day 3 pt (Labbe et al, 1991; Pera et al, 2015; Pourasgari et al, 2007). The RT-PCR assay also confirmed that the VP6 and VP7 mRNA was expressed in transfected Vero Cell at day 1 to 5 pt. RT-PCR products of Vero cells transfected with the pEF/VP6 or pEF/VP7 were expressed with expected fragment of 1.3 kb and 1.1 kb, respectively (Fig. 3).



Figure 2: Protein structure (prediction) of VP2LRV4 (A), VP6LRV4 (B), and VP7LRV4 (C). Dimer forming subdomain of VP2LRV4 in yellow. In silico analysis of VP6LRV4 determined domain B in purple (residues 1-150), domain H (residues 151-331) in gold and residue His-153 that essential in the stabilizing the VP6 trimeric molecule. The VP6LRV4 also contained residues 65-LLGTTLL-71 and Pro313 that may contact with VP2 and VP7. VP7LRV4 contained the conserved N-Glycosylated (Asn-69 and 238) and residues Pro-279 and Thr-281 that may interact with VP6.



Figure 3: Agarose gel electrophoresis of the RT-PCR products obtained from total RNA extracted from Vero cells transfected with the pCMV/VP2, pEF/VP6, and pEF/VP7 genes. Lanes L: 1kb ladder; Lanes 1 to 5: RT-PCR product of VP2 at 1d to 5d post-transfection; Lanes 6 to 10: RT-PCR product of VP6 at 1d to 5d post-transfection; Lanes 11-15: RT-PCR product of VP7 at 1d to 5d post-transfection

Transfected transient cell lines were further examined for the intracellular expression of VP6 and VP7 gene by indirect immunofluorescence assay. As expected, the specific cytoplasmic staining was clearly evident when the transfected cells were reacted with primary polyclonal rabbit anti-rotavirus antibody. The results showed that Vero cells expressed VP6 and VP7 proteins possess a serological specificity similar to that of the viral VP6 and VP7. Our result shows that the transfected Vero cell expressed VP6 and VP7 protein at day 1 to 5 pt (Fig. 4). Interestingly, we observed that the Vero cells transfected with VP7 shows the fluorescence cell with a cell nucleus that more obvious than in the Vero cells transfected with VP6. VP7 is translated at the ribosomes which bind to the membranes of organelles ER while VP6 is translated in polyribosome (Desselberger, 2014). ER membrane lies



Figure 4: Immunofluorescence microscopy analysis of VP6 and VP7 protein that were expressed in Vero cell. The VP6 (A - E) and VP7 (F - J) protein expression of transfected Vero cell was being demonstrated by specific green fluorescence. A and F: day 1 pt; B and G: day 2 pt; C and H: day 3 pt; D and I: day 4 pt; E and J: day 5 pt.

adjacent to the nucleus while polyribosome scattered in the cytoplasm. Those differences may lead to differing form of fluorescence in transfected cell.

CONCLUSION

The three major structural capsid proteins VP2, VP6, and VP7 of human rotavirus RV4 had been isolated and expressed in Vero cell. In silico analysis showed that

the VP2LRV4, VP6LRV4, and VP7LRV4 protein sequences (prediction) comprised essential subdomain and residues to construct triple layer structural capsid protein. Transcriptional analysis confirmed that the VP2 gene was expressed at day 3 post transfection while VP6 and VP7 were expressed at day 1 post transfection. VP6 and VP7 protein expression in transfected Vero cell occurred on day 1 post single transfection. All of it suggested that this study can be developed as a reference on producing triple layer VLP consist of VP2, VP6, and VP7 in Vero cell.

Conflict of interest

The authors declare no conflict of interest with respect to the content and writing of the paper.

Acknowledgement

This work was funded by PT Biofarma, Indonesia and was carried out in partial fulfillment of PhD thesis supported by School of Life Sciences, ITB.

References

Balamurugan V, Sen A, *et al.* (2006) Development and characterization of a stable Vero cell line constitutively expressing peste des petits ruminants virus (PPRV) hemagglutinin protein and its potential use as antigen in enzymelinked immunosorbent assay for sero surveillance of PPRV, *Clin. Vaccine Immunol.*, **13**(12): 8036-8048.

Boudreaux CE, Vile DC, *et al* (2013) Rotavirus core shell subdomains involved in polymerase encapsidation into viruslike particles. *J. Gen. Virol.*, **94**: 1818-1826.

Chen Y, Guo W, *et al.* (2011) A novel recombinant pseudorabies virus expressing parvovirus VP2 gene: immunogenicity and protective efficacy in swine. *Virol J.*, **8**: 307-315.

Chen JZ., Settembre EC, *et al.* (2009) Molecular interaction in rotavirus assembly and uncoating seen by high-resolution cryo-EM. *PNAS*, **103** (26): 10644-10648.

Coulson BS, Kirkwood C., (1991) Relation of VP7 amino acid sequence to monoclonal antibody neutralization of rotavirus and rotavirus monotype. *J. Virol.*, 5968-5974.

Human Rotavirus recombinant protein expression in Vero cell

Da Silva Junior HC, Mouta Junior SS, *et al.* (2012) Comparison of two eukaryotic systems for the expression of VP6 protein of rotavirus specie A: transient gene expression in HEK293-T cells and insect cell-baculovirus system. *Biotechnol. Lett.*, **34**: 1623–1627.

Desselberger U (2014) Rotaviruses. Virus Res., 190: 75-96.

Hsieh PK, Chang SC, *et al.* (2005) Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. *J. Virol.*, **79**(22): 13848-13855.

Hua, RH, Li, YN, *et al.* (2014) Generation and characterization of new mammalian cell line continuously expressing virus-like particle of Javanese encephalitis virus for a subunit vaccine candidate. *BMC Biotechnol.*, **14**: 62-69.

Jager, V, Bussow K, *et al.* (2015) Transient recombinant protein expression in mammalian cells. *Animal Cell Culture, Cell Engineering 9.* Springer International Publishing, ISBN: 978-3-319-10319-8, **12**: 27-63.

Kato T, Deo VK, *et al.* (2012) Functional virus-like particles production using silkworm and their application in life science. *J. Biotechnol. Biomaterial*, S9:001, doi:10.4172/2155-952X.S9-001.

Konisihi E, Fujii A, *et al.* (2001) Generation and characterization of a mammalian cell line continuously expressing japanese encephalitis virus subviral particles. *J. Virol.*, **75** (5): 2204-2212.

Labbe M, Charpilienne A, *et al.* (1991) Expression of rotavirus VP2 produces empty core like particles. *J. Virol.*, **65** (6): 2946-2952.

Mathieu M, Petitpas I, *et al.* (2001) Atomic structure of the major capsid protein of Rotavirus: implication for the architecture of the virion. *EMBO J.*, **20**(7): 1485-1497.

McClain B, Settembre E, *et al.* (2010) X-Ray Crystal structure of the Rotavirus inner capsid particle at 3.8 Å resolution. *J. Mol, Biol.*, **397**: 587-599.

Mulherkar N, Raaben, M, *et al.* (2011) The ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. *Virology*, **419**: 72–83.

Pourasgari, Ahmadian, S, *et al.* (2007) Expression and characterization of VP2 protein of human rotavirus a in a mammalian lung cell line. *Acta Virol*, **51**: 261 – 264.

Pera FFPG, Mutepfa DLR, *et al.* (2015) Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana. *Virol J.*, **12**: 205-211.

Ruiz MC, Leon T, *et al.* (2009) Molecular biology of rotavirus entry and replication, *Sci. World J.*, **9**, 1476–1497.

Rodríguez-Limas WA, Tyo KE, *et al.* (2011) Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. *Microb Cell Fact.*, **10**: 33-43.

Siu YL, Teoh KT, *et al.* (2008) The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles. *J. Virol.*, **82**(22): 11318–11330.

Wagner E, Engelhardt OG, *et al.* (2000) Formation of virus-like particles from cloned cDNAs of thogoto virus. *J. Gen. Virol.*, **81**: 2849–2853.